Study Explores Effectiveness of HTD1801 in Type 2 Diabetes
Real-World Study Supports Ibrutinib Dose Reduction for Managing Adverse Events in CLL
Meta-Analysis of Phase 3 Trials Support Use of Sacituzumab Govitecan Over Physician’s Choice Treatment
Second Dose of IVIG in Guillain-Barré Syndrome Increases Adverse Events Without Major Clinical Benefit